The 4 most recent market catalysts affecting $LMRI, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Oct 5, 2026
Corporate Catalyst
Neutral
Impact 65
Truist Securities Initiates Coverage On Lumexa Imaging Hldgs with Buy Rating, Announces Price Target of $18
Truist Securities analyst Clarke Murphy has initiated coverage on Lumexa Imaging Hldgs (LMRI) with a 'Buy' rating and a price target of $18. This event is significant as new analys…
Sep 25, 2026
Corporate Catalyst
Neutral
Impact 65
Keybanc Initiates Coverage On Lumexa Imaging Hldgs with Overweight Rating, Announces Price Target of $18
Keybanc analyst Matthew Gillmor has initiated coverage on Lumexa Imaging Hldgs (LMRI) with an 'Overweight' rating and an $18 price target. This event is significant because new ana…
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on Lumexa Imaging Hldgs, Raises Price Target to $13
Barclays analyst Andrew Mok maintained an 'Overweight' rating on Lumexa Imaging Hldgs (LMRI) and raised the price target from $9 to $13. This action signals increased confidence fr…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 92
Lumexa Imaging Holdings Q2 Adj. EPS $0.20 Beats $0.16 Estimate, Sales $264.200M Beat $263.113M Estimate
Lumexa Imaging Holdings (LMRI) announced its Q2 earnings, reporting adjusted EPS of $0.20, significantly surpassing the analyst consensus of $0.16. Sales also exceeded expectations…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.